Sol-Gel Announces the Signing of Six Exclusive License Agreements to Commercialize TWYNEO® and EPSOLAY® in Europe and South Africa Sol-Gel Announces the Signing of Six Exclusive License Agreements to Commercialize TWYNEO® and EPSOLAY® in Europe and South Africa

Sol-Gel Technologies Announces Management Realignment Sol-Gel Technologies Announces Management Realignment

Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice

Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel Sol-Gel and Beimei Pharma annouce an Asset Purcase Agreement to commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel